MARKET

AERI

AERI

Aerie Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.11
+0.19
+1.59%
Opening 10:36 09/23 EDT
OPEN
12.02
PREV CLOSE
11.92
HIGH
12.22
LOW
11.90
VOLUME
100.81K
TURNOVER
--
52 WEEK HIGH
21.30
52 WEEK LOW
9.01
MARKET CAP
572.00M
P/E (TTM)
-3.3509
1D
5D
1M
3M
1Y
5Y
BRIEF-Aerie Pharmaceuticals Chairman & CEO Vicente Steps Down; Co Names Benjamin McGraw Interim Executive Chair
reuters.com · 2d ago
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021, Vicente Anido, PhD. no longer serves as ...
Business Wire · 2d ago
BRIEF-Aerie Pharmaceuticals Names Erik Pacyniak Director, Toxicology And Drug Disposition
reuters.com · 3d ago
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and reti...
Business Wire · 3d ago
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win
AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.
Zacks · 6d ago
56 Biggest Movers From Yesterday
   
Benzinga · 6d ago
Hot Stocks: Gold stocks drop; BROS keeps brewing; SPIR takes off; bad data for AERI, SBTX
Commodity prices have played a significant role on Wall Street this week -- a trend that continued Thursday as a drop in gold sparked a slide in mining stocks. Newmont
Seekingalpha · 6d ago
Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge
Toward the end of trading Thursday, the Dow traded down 0.20% to 34,745 while the NASDAQ fell 0.03% to 15,157.61. The S&P also fell, dropping 0.21% to 4,471.34.
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AERI. Analyze the recent business situations of Aerie Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AERI stock price target is 25.45 with a high estimate of 30.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 245
Institutional Holdings: 61.45M
% Owned: 130.10%
Shares Outstanding: 47.23M
TypeInstitutionsShares
Increased
58
3.67M
New
16
434.18K
Decreased
44
3.17M
Sold Out
30
1.71M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.96%
Pharmaceuticals & Medical Research
+1.14%
Key Executives
Chairman/Executive Director
Benjamin Mcgraw
President/Chief Operating Officer
Thomas Mitro
Co-Founder/Chief Scientific Officer
Casey Kopczynski
Chief Financial Officer/Vice President - Finance
Christopher Staten
General Counsel/Secretary
John Larocca
Other
David Hollander
Independent Director
Gerald Cagle
Independent Director
Richard Croarkin
Independent Director
Mechiel Du Toit
Independent Director
David Gryska
Independent Director
Peter Mcdonnell
Independent Director
Julie Mchugh
No Data
About AERI
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Webull offers kinds of Aerie Pharmaceuticals Inc stock information, including NASDAQ:AERI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AERI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AERI stock methods without spending real money on the virtual paper trading platform.